제리스 바이오파마 홀딩스, Inc.
US ˙ NasdaqGS ˙ US98422E1038

SecurityXERS / Xeris Biopharma Holdings, Inc.
InsiderDawn Halkuff
This page shows the track record and history of HALKUFF DAWN insider trades in Xeris Biopharma Holdings, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Dawn Halkuff in XERS / Xeris Biopharma Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-11-20 5,410 1.8400 5,410 1.8400 9,954 354 3.4700 8,819 88.59

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XERS / Xeris Biopharma Holdings, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Dawn Halkuff in XERS / Xeris Biopharma Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-12 42,500 7.2759 42,500 7.2759 309,226 224 5.2900 -84,400 -27.29

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XERS / Xeris Biopharma Holdings, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2026-06-05 2026-06-04 4 HALKUFF DAWN XERS Common Stock A - Award D 24,193 119,193
2026-06-05 2026-06-04 4 HALKUFF DAWN XERS Common Stock S - Sale D 6.0943 -20,000 -122 95,000
2025-08-13 2025-08-12 4 HALKUFF DAWN XERS Common Stock S - Sale D 7.2759 -42,500 -309 115,000
2025-06-04 2025-06-04 4 HALKUFF DAWN XERS Common Stock A - Award D 50,000 157,500
2024-06-05 2024-06-05 4 HALKUFF DAWN XERS Common Stock A - Award D 50,000 107,500
2023-11-21 2023-11-20 4 HALKUFF DAWN By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017 XERS Common Stock P - Purchase I 1.8400 5,410 10 5,410
2023-06-07 2023-06-07 4 HALKUFF DAWN XERS Common Stock A - Award D 42,500 57,500
2022-06-09 2022-06-08 4 HALKUFF DAWN XERS Common Stock A - Award D 15,000 15,000
2021-10-05 2021-10-05 4 HALKUFF DAWN XERS Stock Option (Right to Buy) A - Award D 4.68 11,228 11,228
2021-10-05 2021-10-05 4 HALKUFF DAWN XERS Stock Option (Right to Buy) A - Award D 3.90 11,228 11,228
2021-10-05 2021-10-05 4 HALKUFF DAWN XERS Stock Option (Right to Buy) A - Award D 10.00 20,000 20,000
2021-10-05 2021-10-05 4 HALKUFF DAWN XERS Stock Option (Right to Buy) A - Award D 12.50 19,650 19,650
P
공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매입
S
공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매각
A
자사로부터 유가증권(옵션 등)을 보조, 지급 또는 기타 취득
C
파생상품 전환
D
자사에게 유가증권을 매각 또는 양도
F
기업으로부터 인도 받은 유가증권의 일부를 사용한 행사 가격 또는 조세 채무의 지급
G
내부자에 의한 또는 내부자에게 증권 증여
K
지분스왑 및 유사 위험 회피거래
M
자사로부터 인도 받은 파생증권(옵션 등)의 행사 또는 전환
V
보고서 양식 4에 자진 신고된 거래
J
기타 (거래 내용을 설명하는 각주와 동반)